Pediatric Psychopharmacology for Depressive and Anxiety Disorders
Focus · 2022-04 · 20 (2) · 184-190
DOI: 10.1176/appi.focus.20210036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Focus, 2022-04. Verfasst von Jeffrey R Strawn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Anxiety Disorders Research Program, Department of Psychiatry and Behavioral Neuroscience (Strawn), and Department of Pediatrics, University of Cincin…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Anxiety and depressive disorders are the most common psychiatric illnesses among children and adolescents. These disorders are associated with impairments in social, family, and educational functioning. This article summarizes the evidence base for psychopharmacologic interventions; the developmental pharmacology of selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs); and pharmacokinetic and pharmacodynamic differences between youths and adults that call for differences in dosage and affect response and tolerability. The authors also review the efficacy and tolerability of SSRIs and SNRIs in children and adolescents with depressive and anxiety disorder diagnoses, as well as data related to duration of therapy and SSRI/SNRI discontinuation in this population. Taken together, the current evidence suggests that SSRIs are the first-line psychopharmacologic intervention for youths with depressive and anxiety disorders, with SNRIs having a more limited role. These medications are safe and well tolerated, although emerging data and developmental pharmacologic concepts may help clinicians to choose from available SSRIs and to improve the efficacy and tolerability of these medications in children and adolescents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Anxiety Disorders Research Program, Department of Psychiatry and Behavioral Neuroscience (Strawn), and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati (Strawn, Vaughn); Division of Cli…
Zitieren
APA
Strawn, J. R., Vaughn, S., & Ramsey, L. B. (2022). Pediatric Psychopharmacology for Depressive and Anxiety Disorders. Focus, 20(2), 184-190. https://doi.org/10.1176/appi.focus.20210036
Vancouver
Strawn JR, Vaughn S, Ramsey LB. Pediatric Psychopharmacology for Depressive and Anxiety Disorders. Focus. 2022;20(2):184-190. doi:10.1176/appi.focus.20210036
BibTeX
@article{Strawn2022,
author = {Strawn, Jeffrey R and Vaughn, Samuel and Ramsey, Laura B},
title = {Pediatric Psychopharmacology for Depressive and Anxiety Disorders},
journal = {Focus},
year = {2022},
volume = {20},
number = {2},
pages = {184--190},
doi = {10.1176/appi.focus.20210036}
}
EUVIMED